| Document |
Document Title |
|
WO/2020/006177A1 |
Disclosed herein are small molecule Vascular Adhesion Protein- 1 (VAP-1) modulator compositions, pharmaceutical compositions, the use and preparation thereof.
|
|
WO/2020/005115A1 |
The invention relates to a new class of compounds characterized, in particular, by high antifungal activity, of general formula (I): formula (I) where X and R1-R3 have the values indicated in the description. The invention also relates t...
|
|
WO/2020/006294A1 |
Disclosed herein are methods of treating liver fibrosis by administering calpain inhibitors to subjects in need thereof.
|
|
WO/2019/243414A1 |
The present invention relates to soluble epoxide hydrolase (sEH) inhibitors of formula (I) to processes for their obtention and to their therapeutic indications.
|
|
WO/2019/241533A1 |
This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or condit...
|
|
WO/2019/233328A1 |
The present invention relates to a crystal form of a 4-phenylthiazole derivative, a pharmaceutical composition comprising the same, a preparation method, and a use of the crystal form in preparing a drug for treating thrombocytopenia.
|
|
WO/2019/230848A1 |
This method for producing a polymerizable compound comprises a step (1) for reacting a compound represented by formula (I) and a compound represented by formula (II) in an organic solvent in the presence of a base and/or a dehydration-co...
|
|
WO/2019/229464A1 |
There are described compounds of formula (I): (I) and their use as a medicament in the treatment of diseases associated with the abnormal or elevated catabolism of tryptophan, such as, cancer, immunosuppression, viral infection, depressi...
|
|
WO/2019/226490A1 |
Provided is a compound of Formula (I), wherein the variable groups are defined herein.
|
|
WO/2019/222454A1 |
This disclosure relates to styrylbenzothiazole derivatives for use as in vivo imaging agents for the diagnosis of Parkinson's disease (PD) or other degenerative disorders or conditions of the central nervous system. Early diagnosis is pa...
|
|
WO/2019/218024A1 |
The present invention relates to compounds useful in the modulation of ion channel activity in cells. The invention also relates to use of these compounds in the treatment of pain, and pharmaceutical compositions containing these compoun...
|
|
WO/2019/222134A1 |
The invention relates in one aspect to the identification of compounds that inhibit COUP-TFII activity. In certain embodiments, the compounds of the invention have submicromolar activity against COUP-TFII. In other embodiments, the compo...
|
|
WO/2019/219016A1 |
Provided by the present invention are an acrylic compound and a preparation method therefor and a pharmaceutical composition and application thereof. In particular, the present invention provides a compound of formula I, wherein each gro...
|
|
WO/2019/218418A1 |
Provided in the invention is a preparation method for synthesizing a photosensitive compound through a Claisen-Schmidt reaction. An aldehyde free of alpha-H and a ketone containing alpha-H are selected to be synthesized to obtain the pro...
|
|
WO/2019/222497A1 |
The present disclosure is concerned with 2,5-amino-thiazole compounds that are capable of activating NF-κΒ signaling. The present disclosure is also concerned with methods of using these compounds for the treatment of neurological diso...
|
|
WO/2019/216742A1 |
The present invention relates to: a novel compound exhibiting enteropeptidase inhibitory activity; a pharmaceutically acceptable salt thereof; a pharmaceutical composition for metabolic diseases such as obesity, diabetes, or hyperlipidem...
|
|
WO/2019/217509A1 |
The present invention relates to the field of anti-cancer compounds. More particularly, the invention relates to a family of benzothiazolyi urea or thiorurea compound useful as such agents. The present invention also relates to methods f...
|
|
WO/2019/216653A1 |
The present invention relates to a compound, a complex comprising same, an anti-cancer pharmaceutical composition, and an anti-cancer drug. The compound of the present invention has the structure represented by chemical formula 1 of the ...
|
|
WO/2019/213611A1 |
Provided herein are thiazolidinedione analogues that are useful for treating non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), diabetes, and other metabolic inflammation-mediated disease and disorders.
|
|
WO/2019/207548A1 |
The present invention relates to a process for preparing N-[2-[2-(4-chlorophenyl)-4- thiazolyl] ethyl]-butanamide. The present invention further relates to a pharmaceutical formulation and the use of said pharmaceutical formulation consi...
|
|
WO/2019/208516A1 |
The present invention provides a polymerizable liquid crystal compound which exhibits liquid crystallinity by itself, and which is capable of forming an optically anisotropic body and an optical film that have ideal wavelength dispersion...
|
|
WO/2019/201867A1 |
The invention provides compounds represented by the structural formula (1): wherein R1, R2, R3, R4, R5, R6 are as defined in the claims. The compounds are inhibitors of nucleases, and are useful in particular in a method of treatment and...
|
|
WO/2019/201865A1 |
The invention provides compounds represented by the structural formula (1): wherein R1, R2, R3, R4, R5, R6 are as defined in the claims. The compounds are inhibitors of nucleases, and are useful in particular in a method of treatment and...
|
|
WO/2019/197670A1 |
The present invention relates to the (S)-enantiomer of the chemical compound having the general formula (I); formula (I) wherein R1, and R2 are, equal or independently, aryl, heteroaryl, fused aryl, fused heteroaryl, mono or multi-substi...
|
|
WO/2019/195751A1 |
Compounds of formula (I) wherein, R1, R2, R3, R4a, R4b and R5 are described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as...
|
|
WO/2019/193540A1 |
The invention is directed to substituted heteroaryl derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein A, C, D, L2, L3, R1, R2, R3, R4, R 5, R6, z2, z4, z5, and z6 are as defined herein; or...
|
|
WO/2019/193068A1 |
The present invention relates to a process for the synthesis of a carbon labeled organic compound containing a carbon labeled carboxyl group. The present invention also concerns the use of carbon labeled organic compounds containing a ca...
|
|
WO/2019/192506A1 |
Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders...
|
|
WO/2019/195124A1 |
Compounds of general formula (I), of general formula (II), of general formula (III), of general formula (IV), of general formula (V), of general formula (VI), and their pharmaceutically acceptable salts, wherein all variables are defined...
|
|
WO/2019/185468A1 |
An aqueous composition comprising (a) metal ions comprising tin ions and silver ions and (b) at least one complexing agent of formula (C1) R1-X1-S-X21[D1-X22-]nS-X3-R2, (C2) R1-X1-S-X31-D2-[X32-S-]nX3-R2, (C3) R3-X1-S-X41-[D3-X42-]nS-X3-...
|
|
WO/2019/186498A1 |
Fluoroalkenyl heterocyclic compounds having Formula (I) are described together with agronomic compositions containing said compounds having formula (I) and their use for the control of nematodes in agricultural crops.
|
|
WO/2019/190999A1 |
Disclosed herein are methods of treating fibrotic disorders by administering compounds selective for CAPN1, CAPN2, and/or CAPN9 such that side effects, off pathway interactions, and/or toxicities are minimized. Such methods may, for exam...
|
|
WO/2019/183589A1 |
The present disclosure relates generally to eukaryotic initiation factor 2B modulators of formula A, or a pharmaceutically acceptable salt, stereoisomer, or mixture of stereoisomers thereof and methods of making and using thereof.
|
|
WO/2019/183373A1 |
Disclosed are compounds which may be utilized to inhibit transcription by RNA Polymerase II (Pol II), and in particular to disrupt the Super Elongation Complex (SEC). The compounds may be utilized in pharmaceutical compositions and metho...
|
|
WO/2019/180444A1 |
Polycyclic aromatic hydrocarbons represented by the following general formula (I) wherein X is one of nitrogen, phosphorus, arsenic, antimony, bismuth, sulphur, selenium, tellurium; R independently represents an aromatic group and/or an ...
|
|
WO/2019/177142A1 |
The present invention provides: a prophylactic or therapeutic agent for hypoxic injury, ischaemia-reperfusion injury and inflammation; a cell protection agent for transplantation; and a bio-preservation agent. A prophylactic or therapeut...
|
|
WO/2019/178439A1 |
Benzyl derivative compounds having peroxisome proliferator- activated receptor α (PPARα) agonistic activity, compositions containing such compounds, and methods of their use in enhancing PPARα activity for treating diseases and/or con...
|
|
WO/2019/171277A1 |
The present invention is directed to cycloalkenyl derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the GPR120 and / or GPR40 receptors. 5 More particularly, ...
|
|
WO/2019/166270A1 |
The invention relates to an organic electronic device comprising at least one electron transport, electron injection or electron generation layer comprising a compound of Formula (I) wherein all positions which are not linked to a -(A)a-...
|
|
WO/2019/166269A1 |
The present invention relates to an organic electronic device comprising, between an anode and a cathode, at least one layer selected from an electron injection layer, an electron transport layer or an electron generation layer, the laye...
|
|
WO/2019/166206A1 |
The present invention relates to an organic material and to an electronic device comprising the organic material, particularly to an electroluminescent device, particularly to an organic light emitting diode (OLED), wherein the semicondu...
|
|
WO/2019/165189A1 |
Disclosed are protein arginine methyltransferase 5 (PRMT5) degradation / disruption compounds including a PRMT5 ligand, a degradation / disruption tag and a linker, and methods for use of such compounds in the treatment of PRMT5-mediated...
|
|
WO/2019/165073A1 |
The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further ...
|
|
WO/2019/164788A1 |
The invention provides methods for treating cancer using an aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide compound having RORg agonist activity, such as (S)-3-(6-(3-(difluoromethoxy)-5-fluorophenyl)-4-((3-(trifluo
romethyl)phenyl)sulf...
|
|
WO/2019/160798A1 |
Accelerator solutions containing transition metal complexes based on organic ligands having one or more S-C-N, S-C-C-N, or S-C(=S)-S moieties are useful for accelerating the peroxide cure of resins such as unsaturated polyester resins.
|
|
WO/2019/158607A1 |
The present invention relates to the use of iminooxothiazolidine derivatives for preventing or treating hair growth disorders. The iminooxothiazolidine derivatives may be formulated as compositions suitable for either the systemic admini...
|
|
WO/2019/157020A1 |
In one aspect, the disclosure relates to relates to substituted benzothiophene analogs which are useful as selective degraders of estrogen receptor, methods of making same, pharmaceutical compositions comprising same, and methods of trea...
|
|
WO/2019/153789A1 |
The present invention relates to the technical field of biological imaging, and disclosed thereby are a photo-activated aggregation-induced emission probe having in situ generation capabilities, a preparation thereof and an application t...
|
|
WO/2019/155923A1 |
The present invention addresses the problem of providing a colored photosensitive resin composition capable of forming a color filter having a higher brightness than color filters formed from conventionally known colored photosensitive r...
|
|
WO/2019/151263A1 |
Provided is a method capable of effectively producing a 1,1-disubstituted hydrazine compound that is a target product. In this method for producing a 1,1-disubstituted hydrazine compound represented by formula (II), a hydrazine compound ...
|
